NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate) In a report dated November 30, 2006, American Oriental Bioengineering (AMEX: AOB) was as “Buy/4,” with an increased target valuation of $12, beating analyst’s expectations, reporting revenues of $27 million, net income of $7.6 million and EPS of $0.12 in an “Institutional” Update by Investrend analyst Kipley J. Lytel, CFA.
